Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Survey of antimicrobial resistance in clinical Burkholderia pseudomallei isolates over two decades in Northeast Thailand.

Literature DB >> 21876049

Survey of antimicrobial resistance in clinical Burkholderia pseudomallei isolates over two decades in Northeast Thailand.

Vanaporn Wuthiekanun¹, Premjit Amornchai, Natnaree Saiprom, Narisara Chantratita, Wirongrong Chierakul, Gavin C K W Koh, Wipada Chaowagul, Nicholas P J Day, Direk Limmathurotsakul, Sharon J Peacock.

Abstract

A 21-year survey conducted in northeast Thailand of antimicrobial resistance to parenteral antimicrobial drugs used to treat melioidosis identified 24/4,021 (0.6%) patients with one or more isolates resistant to ceftazidime (n = 8), amoxicillin-clavulanic acid (n = 4), or both drugs (n = 12). Two cases were identified at admission, and the remainder were detected a median of 15 days after starting antimicrobial therapy. Resistance to carbapenem drugs was not detected. These findings support the current prescribing recommendations for melioidosis.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2011 PMID： 21876049 PMCID： PMC3195054 DOI： 10.1128/AAC.05517-11

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

22 in total

1. Comparison of the susceptibilities of Burkholderia pseudomallei to meropenem and ceftazidime by conventional and intracellular methods.

Authors: T J J Inglis; F Rodrigues; P Rigby; R Norton; B J Currie
Journal: Antimicrob Agents Chemother Date: 2004-08 Impact factor: 5.191

2. Halving of mortality of severe melioidosis by ceftazidime.

Authors: N J White; D A Dance; W Chaowagul; Y Wattanagoon; V Wuthiekanun; N Pitakwatchara
Journal: Lancet Date: 1989-09-23 Impact factor: 79.321

3. beta-Lactamase of Pseudomonas pseudomallei and its contribution to antibiotic resistance.

Authors: D M Livermore; P Y Chau; A I Wong; Y K Leung
Journal: J Antimicrob Chemother Date: 1987-09 Impact factor: 5.790

Review 4. The laboratory diagnosis of melioidosis.

Authors: A L Walsh; V Wuthiekanun
Journal: Br J Biomed Sci Date: 1996-12 Impact factor: 3.829

Review 5. Melioidosis: a clinical overview.

Authors: Direk Limmathurotsakul; Sharon J Peacock
Journal: Br Med Bull Date: 2011-05-09 Impact factor: 4.291

6. Multilocus sequence typing and evolutionary relationships among the causative agents of melioidosis and glanders, Burkholderia pseudomallei and Burkholderia mallei.

Authors: Daniel Godoy; Gaynor Randle; Andrew J Simpson; David M Aanensen; Tyrone L Pitt; Reimi Kinoshita; Brian G Spratt
Journal: J Clin Microbiol Date: 2003-05 Impact factor: 5.948

Review 7. Efflux as a mechanism of resistance to antimicrobials in Pseudomonas aeruginosa and related bacteria: unanswered questions.

Authors: Herbert P Schweizer
Journal: Genet Mol Res Date: 2003-03-31

8. Antibiotic susceptibility of Burkholderia pseudomallei from tropical northern Australia and implications for therapy of melioidosis.

Authors: A W Jenney; G Lum; D A Fisher; B J Currie
Journal: Int J Antimicrob Agents Date: 2001-02 Impact factor: 5.283

9. Ceftazidime vs. amoxicillin/clavulanate in the treatment of severe melioidosis.

Authors: Y Suputtamongkol; A Rajchanuwong; W Chaowagul; D A Dance; M D Smith; V Wuthiekanun; A L Walsh; S Pukrittayakamee; N J White
Journal: Clin Infect Dis Date: 1994-11 Impact factor: 9.079

10. The antimicrobial susceptibility of Pseudomonas pseudomallei. Emergence of resistance in vitro and during treatment.

Authors: D A Dance; V Wuthiekanun; W Chaowagul; N J White
Journal: J Antimicrob Chemother Date: 1989-09 Impact factor: 5.790

36 in total

Review 1. Human Melioidosis.

Authors: I Gassiep; M Armstrong; R Norton
Journal: Clin Microbiol Rev Date: 2020-03-11 Impact factor: 26.132

2. Development and validation of a triplex quantitative real-time PCR assay to detect efflux pump-mediated antibiotic resistance in Burkholderia pseudomallei.

Authors: Jessica R Webb; Erin P Price; Nawarat Somprasong; Herbert P Schweizer; Robert W Baird; Bart J Currie; Derek S Sarovich
Journal: Future Microbiol Date: 2018-09-26 Impact factor: 3.165

3. Burkholderia pseudomallei Clinical Isolates Are Highly Susceptible In Vitro to Cefiderocol, a Siderophore Cephalosporin.

Authors: Delaney Burnard; Gemma Robertson; Andrew Henderson; Caitlin Falconer; Michelle J Bauer; Kyra Cottrell; Ian Gassiep; Robert Norton; David L Paterson; Patrick N A Harris
Journal: Antimicrob Agents Chemother Date: 2021-01-20 Impact factor: 5.191

4. Rapid Antimicrobial Susceptibility Testing of Bacillus anthracis, Yersinia pestis, and Burkholderia pseudomallei by Use of Laser Light Scattering Technology.

Authors: Julia V Bugrysheva; Christine Lascols; David Sue; Linda M Weigel
Journal: J Clin Microbiol Date: 2016-03-16 Impact factor: 5.948

5. Membrane-Bound PenA β-Lactamase of Burkholderia pseudomallei.

Authors: Linnell B Randall; Karen Dobos; Krisztina M Papp-Wallace; Robert A Bonomo; Herbert P Schweizer
Journal: Antimicrob Agents Chemother Date: 2015-12-28 Impact factor: 5.191

Review 6. Mechanisms of antibiotic resistance in Burkholderia pseudomallei: implications for treatment of melioidosis.

Authors: Herbert P Schweizer
Journal: Future Microbiol Date: 2012-12 Impact factor: 3.165

7. Disarming Burkholderia pseudomallei: structural and functional characterization of a disulfide oxidoreductase (DsbA) required for virulence in vivo.

Authors: Philip M Ireland; Róisín M McMahon; Laura E Marshall; Maria Halili; Emily Furlong; Stephanie Tay; Jennifer L Martin; Mitali Sarkar-Tyson
Journal: Antioxid Redox Signal Date: 2013-09-20 Impact factor: 8.401